Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus
Grewal S, Zaman N, Borgatta L, et al.
Am J Cardiol. 2021;S0002-9149(21)00522-1.
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Grewal S, Zaman N, Borgatta L, et al.
Am J Cardiol. 2021;S0002-9149(21)00522-1.
Leggi
Frías JP, Davies MJ, Rosenstock J, et al.
N Engl J Med. Pub. online 25 June 2021.
Leggi
Park HW, Kim YG, Park GM, et al.
Am J Cardiol. 2021;S0002-9149(21)00493-8.
Leggi
Gerstein HC, Sattar N, Rosenstock J, et al.
NEJM. Pub. online 28 June 2021.
Leggi
Søholm, JC, Vestgaard M, Ásbjörnsdóttir B, et al.
Diabetologia. Pub. online 19 Jun 2021.
Leggi
Jacobson AM, Ryan CM, Braffett BH, et al.
Lancet Diabetes Endocrinol. 2021;9(7):436-445.
Leggi
Noor N, Ebekozien O, Levin L, et al.
Diabetes Care. 2021;dc210074.
Leggi
Ceriello A
Diabetes Res Clin Pract. 2021;108864.
Leggi
Karter AJ, Parker MM, Moffet HH, et al.
JAMA. 2021;325(22):2273-2284.
Leggi
Lamprea–Montealegre JA, Katz R, Scharnagl H, et al.
The American Journal of Cardiology. Pub. online 6 June 2021
Leggi